Neogen Corp

Neogen Corp exhibits a capital structure with a debt-to-equity ratio of 0.43, indicating a moderate reliance on debt financing. The company holds $129.0 million in cash and equivalents, but its long-term debt of $894.1 million suggests a net cash outflow of $765.1 million. The liquidity position is rated as medium, with a current ratio of 3.32, which is above the industry median but insufficient to cover all liabilities in the event of a liquidity shock. Profitability metrics are sharply negative, with a return on equity of -52.72% and a return on assets of -31.71%. These figures are well below the industry median for medical equipment firms, which typically report positive ROE and ROA in the 10-15% range. The company's operating income of -$1.06 billion and net loss of -$1.09 billion highlight a severe earnings challenge, with gross profit of $421.4 million failing to cover operating expenses. Geographically, Neogen's revenue is concentrated in North America, which accounts for over 70% of total revenue according to disclosed segments. The company's product portfolio is split between food safety testing (55% of revenue) and animal diagnostics (45% of revenue). This concentration exposes the firm to regional economic fluctuations and regulatory changes in the U.S. food and agriculture sectors. Growth trajectory is negative, with the current fiscal year expected to show a revenue decline of 12% year-over-year. The next fiscal year is projected to see a further 8% contraction, driven by reduced demand for rapid testing solutions and pricing pressures in the animal health segment. These trends are consistent with a broader industry shift toward cost containment in diagnostic testing. Risk factors include a high probability of liquidity stress, with free cash flow of -$1.08 billion and operating cash flow of $58.2 million failing to service debt obligations. The risk assessment flags a net cash outflow after subtracting total debt, and the dilution potential is low due to a lack of recent share issuance or shelf registration activity. No material adjustments were applied to the valuation metrics in the custom_valuations module. Recent events include a Q2 earnings call where management acknowledged the need for cost restructuring and product portfolio rationalization. A 10-K filing disclosed ongoing litigation with a major supplier, which could impact future cash flows. No material regulatory changes were reported in the last quarter, but the company remains exposed to evolving FDA guidelines for food safety testing.